D R Gandara

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Angela M Davies
    Davis Cancer Center, University of California, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Invest New Drugs 25:351-5. 2007
  2. ncbi Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial
    Y Yen
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Am J Clin Oncol 31:317-22. 2008
  3. ncbi Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA, USA
    J Thorac Oncol 1:S20-6. 2006
  4. ncbi Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition
    David R Gandara
    University of California Davis Cancer Center, Sacramento, California, USA
    Clin Cancer Res 10:4205s-4209s. 2004
  5. ncbi Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer
    David Gandara
    Department of Internal Medicine, Division of Hematology Oncology and Department of Radiation Oncology, UC Davis Cancer Center, University of California Davis Medical Center, 4501 X Street, Sacramento, CA 95817, USA
    Clin Cancer Res 11:5057s-5062s. 2005
  6. ncbi Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics
    David R Gandara
    University of California Davis Cancer Center, 4501 X St, Suite 3017, Sacramento, CA 95817 2229, USA
    J Clin Oncol 27:3540-6. 2009
  7. ncbi Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:S61-7. 2007
  8. ncbi Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy
    David R Gandara
    Department of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817 2229, USA
    Clin Lung Cancer 7:S93-7. 2005
  9. ncbi Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:116-21. 2006
  10. ncbi Gemcitabine/carboplatin combination regimens: importance of dose schedule
    D R Gandara
    University of California, Davis Cancer Center, Sacramento, USA
    Oncology (Williston Park) 14:26-30. 2000

Research Grants

  1. Southwest Oncology Group/ University of California,
    David Gandara; Fiscal Year: 2007
  2. Southwest Oncology Group/ University of California,
    David Gandara; Fiscal Year: 2007

Detail Information

Publications108 found, 100 shown here

  1. ncbi Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Angela M Davies
    Davis Cancer Center, University of California, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Invest New Drugs 25:351-5. 2007
    ....
  2. ncbi Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial
    Y Yen
    Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Am J Clin Oncol 31:317-22. 2008
    ..Oxaliplatin has recently demonstrated activity in HCC. The objective of this study was to determine the response rate, survival, time to progression, and toxicity in patients with poor prognosis HCC when treated with oxaliplatin...
  3. ncbi Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA, USA
    J Thorac Oncol 1:S20-6. 2006
    ....
  4. ncbi Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition
    David R Gandara
    University of California Davis Cancer Center, Sacramento, California, USA
    Clin Cancer Res 10:4205s-4209s. 2004
    ..These studies provide a biological rationale for investigating BAC as a model of predictive markers of EGFR inhibition...
  5. ncbi Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer
    David Gandara
    Department of Internal Medicine, Division of Hematology Oncology and Department of Radiation Oncology, UC Davis Cancer Center, University of California Davis Medical Center, 4501 X Street, Sacramento, CA 95817, USA
    Clin Cancer Res 11:5057s-5062s. 2005
    ..Here, we describe conceptual issues, preclinical rationale, and ongoing or planned clinical trials incorporating NTAs into current treatment paradigms for unresectable stage III NSCLC...
  6. ncbi Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics
    David R Gandara
    University of California Davis Cancer Center, 4501 X St, Suite 3017, Sacramento, CA 95817 2229, USA
    J Clin Oncol 27:3540-6. 2009
    ..This common-arm approach facilitates the prospective study of population-related pharmacogenomics in which ethnic differences in antineoplastic drug disposition are anticipated...
  7. ncbi Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:S61-7. 2007
    ....
  8. ncbi Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy
    David R Gandara
    Department of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817 2229, USA
    Clin Lung Cancer 7:S93-7. 2005
    ..Herein, we review the rationale for a treatment paradigm employing consolidation docetaxel therapy after concurrent chemotherapy/RT and the results of recent clinical trials using this approach...
  9. ncbi Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:116-21. 2006
    ..Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation...
  10. ncbi Gemcitabine/carboplatin combination regimens: importance of dose schedule
    D R Gandara
    University of California, Davis Cancer Center, Sacramento, USA
    Oncology (Williston Park) 14:26-30. 2000
    ..This article describes recent clinical trials evaluating gemcitabine plus carboplatin, and the impact of the dosing schedule on the feasibility and tolerability of this combination...
  11. ncbi Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer
    David R Gandara
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 5:1933-8. 2010
    ..We investigated the relationship of EGFR mutation status and DNA repair capacity, as exemplified by excision repair cross-complementing 1 (ERCC1) gene expression, as a potential explanation for this observation...
  12. ncbi Adjuvant chemotherapy of stage I non-small cell lung cancer in North America
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 2:S125-7. 2007
    ..We review data regarding adjuvant therapy of stage I NSCLC from clinical trials performed in North America and Europe. Pertinent trials from Japan are discussed elsewhere in this issue...
  13. ncbi Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)
    Angela M Davies
    Department of Hematology Oncology, University of California, Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:87-92. 2009
    ..This phase II study of bortezomib in combination with gemcitabine/carboplatin was conducted in chemotherapy-naive advanced NSCLC patients to assess efficacy and safety...
  14. ncbi Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, USA
    J Clin Oncol 21:2004-10. 2003
    ..Nevertheless, this study remains hypothesis-generating and does not provide definitive evidence of the benefit of this approach. Phase III trials evaluating the S9504 regimen have been initiated to validate these results...
  15. ncbi Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel
    M J Edelman
    Cancer Center, University of California Davis, Davis, California, USA
    Cancer 92:146-52. 2001
    ....
  16. ncbi Promising new agents in the treatment of non-small cell lung cancer
    M J Edelman
    Division of Hematology and Oncology, University of California, Davis, USA
    Cancer Chemother Pharmacol 37:385-93. 1996
    ..The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed...
  17. ncbi Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
    P N Lara
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento 95817, USA
    Cancer Chemother Pharmacol 48:22-8. 2001
    ..In view of these findings, we hypothesized that toremifene would reverse platinum resistance and that this interaction would be influenced by tumor estrogen receptor (ER) status...
  18. ncbi Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy
    Tatsuo Kimura
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    Ann N Y Acad Sci 1022:55-60. 2004
    ..It was concluded that detection of tumor DNA in plasma is feasible using molecular techniques and that this approach shows promise for monitoring patient response to therapy...
  19. ncbi Developing targeted therapies for lung cancer
    David R Gandara
    University of California, Davis Cancer Center, USA
    Clin Adv Hematol Oncol 1:648-9, 690. 2003
  20. ncbi Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222
    Quynh Thu X Le
    Stanford University, Stanford, CA, USA
    J Clin Oncol 27:3014-9. 2009
    ..We report results of the phase II study designed to confirm this result...
  21. ncbi Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma
    Philip C Mack
    Cancer and Molecular Research Laboratory, Division of Hematology/Oncology, Department of Internal Medicine, University of California, Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Cancer Chemother Pharmacol 51:337-48. 2003
    ..These findings support the hypothesis that checkpoint abrogation is the major mechanism of UCN-01-mediated potentiation of cisplatin cytotoxicity...
  22. ncbi Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer
    Angela Davies
    Division of Hematology/Oncology, University of California Davis Cancer Center, Sacramento, CA 95817-2229, USA
    Semin Oncol 29:10-6. 2002
    ....
  23. ncbi Neoadjuvant therapy for non-small cell lung cancer
    D R Gandara
    Division of Hematology and Oncology, UC Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Anticancer Drugs 12:S5-9. 2001
    ..Preliminary studies have confirmed the feasibility of integrating docetaxel into neoadjuvant treatment strategies and encouraging results have been reported...
  24. ncbi Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:862-8. 2009
    ..Pharmacodynamic separation by intermittent delivery of epidermal growth factor receptor tyrosine kinase inhibitors with chemotherapy may increase efficacy by overcoming hypothesized antagonism...
  25. ncbi Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial
    Przemyslaw Twardowski
    City of Hope Cancer Ctr, Duarte, CA, USA
    Urology 76:923-6. 2010
    ..Evidence has shown that vascular endothelial growth factor is important in the pathophysiology of urothelial cancer...
  26. ncbi SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4772-81. 2003
    ..Efficacy was correlated with serial plasma VEGF and plasminogen activator inhibitor-1 levels and with positron emission tomography scans...
  27. ncbi Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2
    Paul J Hesketh
    Division of Hematology Oncology, Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts, USA
    J Thorac Oncol 3:1026-31. 2008
    ..Exploratory analyses of a number of biomarkers relating to epidermal growth factor receptor pathway activation were also performed...
  28. ncbi Population-based maximum tolerated dose of irinotecan and carboplatin
    Carolyn A Wild
    University of California, Davis Cancer Center, Veterans Administration, Northern California Health Care System, Sacramento, California, USA
    Oncology (Williston Park) 17:11-6. 2003
    ..We recommend dose level 1 of irinotecan (200 mg/m2) and carboplatin (AUC 5) for chemotherapynaive patients, and dose level-1 of irinotecan (150 mg/m2) and carboplatin (AUC 5) for chemotherapy-treated patients in phase II trials...
  29. ncbi Phase I trial of gemcitabine and paclitaxel in advanced solid tumors
    Nelson Lim
    Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis School of Medicine, Sacramento, California, USA
    Cancer Invest 21:7-13. 2003
    ..The recommended phase II dose is gemcitabine 1000 mg/m2 and paclitaxel 150 mg/m2 on days one and eight every 21 days. The antitumor activity observed with this regimen warrants further investigation...
  30. ncbi Gemcitabine in combination with new platinum compounds: an update
    D R Gandara
    Division of Hematology/Oncology, University of California, Davis Cancer Center, Sacramento, California, USA
    Oncology (Williston Park) 15:13-7. 2001
    ..Here we review recent studies investigating gemcitabine plus carboplatin and preliminary data regarding combinations of gemcitabine with the new platinum analog oxaliplatin...
  31. ncbi Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy
    Primo N Lara
    Department of Internal Medicine, University of California Davis School of Medicine, UCD Cancer Center, Sacramento 95817, USA
    Semin Oncol 31:40-6. 2004
    ..PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer...
  32. ncbi Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia
    David R Gandara
    Division of Hematology-Oncology and the Department of Radiation Oncology, University of California, Sacramento, CA 95817, USA
    Semin Oncol 29:102-9. 2002
    ..This article reviews the preclinical and clinical development of tirapazamine, as well as current trials in non-small cell lung cancer designed to provide proof of principle for this new category of cancer therapeutics...
  33. ncbi Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care
    Frederick J Meyers
    Department of Internal Medicine, Cancer Center, The University of California Davis Health System, Sacramento, California 95817, USA
    J Pain Symptom Manage 28:548-56. 2004
    ..SC may enhance coordination of care and facilitate patients' explicit transition from curative intent to palliative intent. In order to validate this approach, a randomized comparative trial evaluating SC has been initiated...
  34. ncbi Natural history of stage I non-small cell lung cancer: implications for early detection
    Dan J Raz
    University of California, San Francisco, 513 Parnassus Ave, S 321, San Francisco, CA 94131, USA
    Chest 132:193-9. 2007
    ..Our hypothesis is that long-term survival in patients with untreated stage I non-small cell lung cancer (NSCLC) is uncommon...
  35. ncbi Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity
    Royce Calhoun
    UC Davis Cancer Center, California, USA
    Oncology (Williston Park) 22:511-6; discussion 516, 521-3. 2008
    ..In addition, the authors consider current treatment options for stage IB NSCLC and review planned clinical trials for stage I disease designed to exploit new pharmacogenomic findings...
  36. ncbi Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma
    Ken Y Yoneda
    Division of Pulmonary Medicine, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA
    Clin Lung Cancer 8:S31-5. 2006
    ..The mortality remains high at approximately 30%-50%. We present a review of the incidence, risk factors, clinical manifestations, diagnosis, management, and outcome of this disorder...
  37. ncbi Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 1:126-34. 2006
    ..This phase I study was performed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of docetaxel in combination with bortezomib in patients with advanced non-small cell lung cancer (NSCLC) or other solid tumors...
  38. ncbi Aurora kinase inhibitors: a new class of targeted drugs in cancer
    Oliver Gautschi
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:93-8. 2006
    ..This article reviews the biology of aurora kinases, their potential role in the treatment of lung cancer, and challenges in the clinical development of this unique class of antineoplastic agents...
  39. ncbi Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712
    Angela M Davies
    University of California, Davis, Sacramento, CA, USA
    J Clin Oncol 24:5242-6. 2006
    ..This study evaluated adding consolidation paclitaxel after chemoradiotherapy for a similar patient cohort...
  40. ncbi Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer 116:5710-5. 2010
    ..Because 0124 and 9511 used identical treatment regimens and similar eligibility criteria, patient-level data were pooled from both trials, and a common arm analysis was performed to explore potential reasons for the divergent results...
  41. ncbi Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327)
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    J Thorac Oncol 1:996-1001. 2006
    ..We conducted a phase II trial of PS-341 in previously treated patients with platinum-sensitive and -refractory extensive stage SCLC to determine response rate, toxicity, and survival...
  42. ncbi Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer
    Ken Y Yoneda
    Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, UC Davis School of Medicine, Sacramento, California 95817, USA
    J Thorac Oncol 2:537-43. 2007
    ..The primary focus of this blinded review was to determine the incidence of ILD leading to death in 1059 TRIBUTE patients randomized to chemotherapy plus erlotinib or placebo...
  43. ncbi A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Anticancer Drugs 20:179-84. 2009
    ..Strong preclinical evidence warrants further investigation of AZD0530 in earlier-stage prostate cancer or as combination therapy...
  44. ncbi Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier
    Randeep Sangha
    University of California, Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Curr Opin Oncol 21:116-23. 2009
    ..Several lines of evidence suggest that these novel approaches may play a relevant role in the future treatment of NSCLC...
  45. ncbi Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer
    Helen K Chew
    Department of Internal Medicine, Division of Hematology Oncology, University of California Davis, Sacramento, CA 95817, USA
    J Clin Oncol 27:2163-9. 2009
    ..Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes...
  46. ncbi The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells
    Phillip R Purnell
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:448-54. 2009
    ..This will facilitate the development of tests to identify patients who may benefit from these agents, allow drug activity to be monitored and rationalize the combination of these agents with other treatment modalities...
  47. ncbi Predictive molecular markers: has the time come for routine use in lung cancer?
    Angela M Davies
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California, USA
    J Natl Compr Canc Netw 2:125-31. 2004
    ..To date, none of these markers can be recommended for routine use in clinical practice...
  48. ncbi Cooperative group research endeavors in small-cell lung cancer: current and future directions
    Randeep Sangha
    Division of Hematology Oncology, University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 10:322-30. 2009
    ..Continued research efforts sponsored by these groups will represent the future of SCLC diagnosis and management...
  49. ncbi Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer
    Tianhong Li
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Curr Drug Targets 11:85-94. 2010
    ..Ongoing research efforts investigating this concept are reviewed...
  50. ncbi Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials
    Primo N Lara
    University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA
    J Clin Oncol 26:463-7. 2008
    ....
  51. ncbi Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation
    Christopher M Mahaffey
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:548-53. 2007
    ..We hypothesized that the lack of benefit resulted from a negative interaction between chemotherapy and EGFR TKIs...
  52. ncbi The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study
    Angela M Davies
    Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA
    J Thorac Oncol 3:68-74. 2008
    ..The combination of gemcitabine and carboplatin is an accepted first-line treatment for advanced NSCLC. We conducted a phase I study of gemcitabine and carboplatin in combination with bortezomib...
  53. ncbi Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
    Angela M Davies
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 2:1112-6. 2007
    ..We examined the safety and tolerability of pemetrexed in combination with two different schedules of bortezomib in patients with advanced solid tumors...
  54. ncbi EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer
    Philip C Mack
    Division of Hematology and Oncology, University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 4:1466-72. 2009
    ..We hypothesized that analysis of plasma for EGFR and KRAS mutations from shed tumor DNA would have clinical utility...
  55. ncbi Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer
    Angela M Davies
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 7:385-8. 2006
    ..Herein we provide the preclinical and clinical rationale for studies examining the concept of pharmacodynamic separation as a means for overcoming hypothesized antagonism of EGFR TKIs and chemotherapy...
  56. ncbi Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 27:2530-5. 2009
    ..To confirm those results and discern the potential role of population-related pharmacogenomics (PG) in outcomes, we conducted a large randomized trial of identical design to the Japanese trial in North American patients with E-SCLC...
  57. ncbi Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial
    Primo N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California 95817, USA
    Cancer 100:2125-31. 2004
    ..The authors screened for HER-2 overexpression in patients developing hormone-refractory prostate carcinoma (HRPC) and conducted a Phase II trial of trastuzumab plus docetaxel in HER-2-positive patients...
  58. ncbi Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 6:102-7. 2004
    ..06). We concluded that salvage gemcitabine in this dose and schedule is safe and tolerable in previously platinum-treated patients with NSCLC...
  59. ncbi Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells
    Philip C Mack
    Cancer and Molecular Research Laboratory, Division of Hematology Oncology, Department of Internal Medicine, Sacramento, California 95817, USA
    Radiat Res 162:623-34. 2004
    ..These studies indicate that simultaneous elimination of multiple DNA damage-induced checkpoints in G(1), S and G(2) may enhance the effects of radiation and that drug scheduling may have an impact on clinical efficacy...
  60. ncbi Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Anticancer Drugs 16:317-21. 2005
    ..Three of these prolonged stable disease patients had non-small cell lung cancer. We conclude that intermittent dosing of R115777 is feasible and tolerable. The recommended phase II dose is 600 mg orally b.i.d. on alternate weeks...
  61. ncbi Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved
    Peter F Roberts
    Division of Cardiothoracic Surgery, University California, Davis Medical Center, Sacramento, 95817, USA
    J Thorac Cardiovasc Surg 126:1597-602. 2003
    ..The staging and treatment of multifocal non-small cell cancer are controversial. We evaluated the current staging of multifocal bronchioloalveolar carcinoma and the therapeutic effectiveness of resection when this tumor type is involved...
  62. ncbi Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study
    Primo N Lara
    California Cancer Consortium at the University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4356-62. 2003
    ..We conducted a Phase I study of tirapazamine, carboplatin, and paclitaxel and assessed potential plasma markers of hypoxia as surrogates for response...
  63. ncbi Docetaxel in non-small cell lung cancer: a review
    Angela M Davies
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Expert Opin Pharmacother 4:553-65. 2003
    ..This paper will review the pharmacology, preclinical, clinical and pharmacoeconomic data supporting the use of docetaxel in the treatment NSCLC...
  64. ncbi The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 11:4444-50. 2005
    ..Our group has previously shown that UCN-01 potentiates the apoptotic response of agents such as cisplatin in vitro by preventing sequence-specific abrogation of G2 arrest caused by DNA-damaging chemotherapies...
  65. ncbi Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Cancer Invest 21:1-6. 2003
    ..Tamoxifen has been reported to enhance the antitumor activity of cisplatin in preclinical models by modulation of protein kinase C signal transduction and apoptosis-related pathways...
  66. ncbi A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases
    Primo N Lara
    University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA
    Clin Cancer Res 12:1556-63. 2006
    ..Serial serum and urine specimens were collected to assess for markers of bone metabolism...
  67. ncbi Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial
    Primo N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 5:231-6. 2004
    ..In view of the limited target population for HER2 inhibition, future efforts and resources should be directed toward molecular targets other than HER2 in NSCLC...
  68. ncbi Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S67-71. 2005
    ..Bortezomib is a proteasome inhibitor that can decrease Bcl-2 expression through diminished IkappaB degradation. Efforts to promote apoptosis in SCLC through the integration of bortezomib into therapy are under way...
  69. ncbi Bortezomib-based combinations in the treatment of non-small-cell lung cancer
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S59-63. 2005
    ..This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date...
  70. ncbi Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 23:9282-9. 2005
    ..We evaluated the level of awareness of patients and/or their family members/friends regarding CCTs and SB37...
  71. ncbi Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 12:33-7. 2011
    ..A prospective randomized phase II trial of concurrent versus sequential docetaxel and bortezomib was conducted to assess whether administration sequence resulted in measurable clinical differences...
  72. ncbi Incorporating bortezomib into the treatment of lung cancer
    Angela M Davies
    UC Davis Cancer Center, University of California, Sacramento, California 95817, USA
    Clin Cancer Res 13:s4647-51. 2007
    ..Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma...
  73. ncbi Treatment of extensive small cell lung cancer
    Angela M Davies
    University of California-Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Hematol Oncol Clin North Am 18:373-85. 2004
  74. ncbi Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003
    Philip C Mack
    Division of Hematology and Oncology, University of California, Davis Cancer Center, 4501 X St, Ste 3016, Sacramento, CA 95817, USA
    J Clin Oncol 26:4771-6. 2008
    ..We investigated the relationship between clinical outcomes and plasma levels of the hypoxia-associated protein osteopontin (OPN) in patients on this protocol...
  75. ncbi Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817-2229, USA
    Clin Lung Cancer 7:353-6. 2006
  76. ncbi Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
    Philip C Mack
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Lung Cancer 41:S89-96. 2003
    ..PS-341 is currently in phase I/II clinical development in lung cancer. This paper will review the pre-clinical and clinical experience with PS-341 as it relates to lung cancer...
  77. ncbi Non-small-cell lung cancer progression after first-line chemotherapy
    Primo N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Curr Treat Options Oncol 3:53-8. 2002
    ..In view of the recently established role of docetaxel, ongoing randomized studies are using a common design of single-agent docetaxel versus docetaxel plus a novel investigational agent...
  78. ncbi HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial
    Primo N Lara
    University of California Davis Cancer Center, Division of Hematology Oncology, 4501 X Street, Sacramento, CA 95817, USA
    Cancer 94:2584-9. 2002
    ..The authors report the results of HER-2 screening from a Phase II trial of chemotherapy with trastuzumab and docetaxel in patients with HER-2-overexpressing prostate carcinoma...
  79. ncbi Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen
    P J Hesketh
    Division of Hematology Oncology, St Elizabeth s Medical Center, Boston, MA 02135 2907, USA
    Support Care Cancer 8:46-8. 2000
    ..Control of delayed emesis was not better than with current standard treatment, and more effective approaches are needed...
  80. ncbi Origin and prognostic value of circulating KRAS mutations in lung cancer patients
    O Gautschi
    University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Cancer Lett 254:265-73. 2007
    ..These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer...
  81. ncbi Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment
    P N Lara
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    J Clin Oncol 19:1728-33. 2001
    ..Unfortunately, only 3% of new cancer patients participate in clinical trials. Barriers to patient accrual in cancer clinical trials must be identified and overcome to increase patient participation...
  82. ncbi Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019
    Kathy S Albain
    Loyola University Stritch School of Medicine, Maywood, IL, USA
    J Clin Oncol 20:3454-60. 2002
    ..These results also justify use of the SWOG-9019 approach as a control arm in ongoing phase III trials...
  83. ncbi Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713
    Martin J Edelman
    Southwest Oncology Group (S9713, Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217, USA
    J Clin Oncol 22:127-32. 2004
    ..This study and others which have tested paclitaxel in small-cell lung cancer dampens enthusiasm for this agent in the primary management of LSCLC...
  84. ncbi Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126
    Howard L West
    Swedish Cancer Institute/Puget Sound Oncology Consortium, Seattle, WA, USA
    J Clin Oncol 24:1807-13. 2006
    ..003), never-smokers (P = .061), and patients with a PS of 0 or 1 (P = .015). CONCLUSION: Gefitinib is an active agent in advanced stage BAC. Several subsets demonstrate significantly improved clinical outcomes...
  85. ncbi Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003
    Stephen K Williamson
    University of Kansas Medical Center, Kansas City, KS, USA
    J Clin Oncol 23:9097-104. 2005
    ..003). CONCLUSION: The addition of tirapazamine to paclitaxel and carboplatin does not result in improved survival in advanced NSCLC compared with paclitaxel and carboplatin alone but substantially increases toxicity...
  86. ncbi Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer
    Martin J Edelman
    Division of Hematology/Oncology, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201-1595, USA
    Lung Cancer 39:197-9. 2003
    ..In 40% of patients there was evidence of disease stabilization. Toxicity at 1.5 mg/m(2) was unacceptable. Since activity and toxicity may be dose and schedule dependent, other schedules of cryptophycin 52 should be considered...
  87. ncbi Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer
    Scott D Ramsey
    Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 94:291-7. 2002
    ..There were no statistically significant differences in survival or cancer-related quality of life between the treatment arms...
  88. ncbi Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
    Fred R Hirsch
    Southwest Oncology Group, San Antonio, USA
    J Clin Oncol 26:3351-7. 2008
    ..Here, we evaluate EGFR FISH as a predictive marker in NSCLC patients receiving the EGFR monoclonal antibody inhibitor cetuximab plus chemotherapy...
  89. ncbi Novel agents in the treatment of lung cancer: conference summary statement
    Thomas J Lynch
    Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Cancer Res 10:4199s-4204s. 2004
  90. ncbi Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
    J Thorac Oncol 2:440-4. 2007
    ..This phase II study (S9718) evaluated the antineoplastic activity and tolerability of the combination of gemcitabine and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ES-SCLC)...
  91. ncbi Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement
    Thomas J Lynch
    Division of Hematology/Oncology and Dana-Farber/Partners Cancer Care, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Clin Cancer Res 11:4981s-4983s. 2005
  92. ncbi Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study
    Fred R Hirsch
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Clin Oncol 23:6838-45. 2005
    ..Epidermal growth factor receptor (EGFR) inhibitors demonstrated response rates of 20% to 30% in patients with advanced BAC subtypes, but selection methods for patient therapy are not established...
  93. ncbi Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
    David R Gandara
    J Clin Oncol 23:5856-8. 2005
  94. ncbi Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, MA 02135, USA
    J Thorac Oncol 1:991-5. 2006
    ....
  95. ncbi Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027)
    Paul J Hesketh
    Caritas St. Elizabeth's Medical Center of Boston, Boston, MA, USA
    J Thorac Oncol 1:537-44. 2006
    ..CONCLUSION: Sequential vinorelbine and docetaxel is a well-tolerated and effective regimen in comparison with reports of other treatments tested in patients with advanced NSCLC age 70 and older and/or with a PS of 2...
  96. ncbi Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer
    Luis Paz-Ares
    Servicio de Oncologia Medica, Doce de Octubre University Hospital, Madrid, Spain
    J Clin Oncol 24:1428-34. 2006
    ....
  97. ncbi Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial
    Heather A Wakelee
    Stanford Cancer Center, CA 94305 5826, USA
    Clin Lung Cancer 8:18-21. 2006
    ..Because of the recent update, this trial will now limit patients with stage IB disease to those with larger tumors (>or= 4 cm) and will likely include only cisplatin-based regimens...
  98. ncbi Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study
    Wolfram E Samlowski
    University of Utah Health Science Center, Salt Lake City, Utah, USA
    Cancer Invest 25:182-8. 2007
    ..8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status...
  99. ncbi Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
    J Thorac Oncol 2:494-8. 2007
    ....
  100. ncbi First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay
    Fred R Hirsch
    Division of Medical Oncology, University of Colorado, Health Sciences Center, Aurora, CO, USA
    J Thorac Oncol 3:S138-42. 2008
    ....
  101. ncbi Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer
    Lawrence H Einhorn
    Indiana Cancer Pavilion, Indianapolis, Indiana, USA
    J Thorac Oncol 3:545-55. 2008

Research Grants4

  1. Southwest Oncology Group/ University of California,
    David Gandara; Fiscal Year: 2007
    ..Thus, UCD is particularly well positioned to take full advantage of new opportunities for facilitating and coordinating SWOG-related clinical research studies in North-Central California. ..
  2. Southwest Oncology Group/ University of California,
    David Gandara; Fiscal Year: 2007
    ..Thus, UCD is particularly well positioned to take full advantage of new opportunities for facilitating and coordinating SWOG-related clinical research studies in North-Central California. ..